Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 26 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II StudyRecruitingNCT04462965Phase 2
• A Phase 1/2 Study of TY101 for Locally Advanced /Metastatic Solid Tumors and Relapsed or Refractory LymphomasRecruitingNCT04458389Phase 1/2
• Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II StudyRecruitingNCT04454905Phase 2
• Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal CarcinomaRecruitingNCT04453826Phase 3
• Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal CarcinomaNot yet recruitingNCT04447326Phase 2
• An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal CancerNot yet recruitingNCT04443543Phase 2
• Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )RecruitingNCT04443322Not applicable
• Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)RecruitingNCT04434040Phase 2
• Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular CarcinomaRecruitingNCT04430452Phase 2
• PLATFORM Study of Precision Medicine for Rare TumorsRecruitingNCT04423185Phase 2
• Pembrolizumab, Ibrutinib and Rituximab in PCNSLRecruitingNCT04421560Phase 1/2
• A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck CancerNot yet recruitingNCT04405154Phase 2
• The IMmunotherapy Pleural 5-ALA PDTRecruitingNCT04400539Phase 2
• Avelumab and Methotrexate in in Low-risk Gestational Trophoblastic Neoplasias as First Line TreatmentRecruitingNCT04396223Phase 1/2
• Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar CancerRecruitingNCT04380545Phase 1/2
• Toripalimab for Local-regional Recurrent Nasopharyngeal CarcinomaRecruitingNCT04376866Phase 3
• Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer PatientsRecruitingNCT04375956Phase 2
• Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)RecruitingNCT04374305Phase 2
• A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT04370587Phase 1/2
• A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy with or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)RecruitingNCT04365036Phase 3
• Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast CancerRecruitingNCT04348747Phase 2
• Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJCRecruitingNCT04342910Phase 3
• ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingNCT04341181Phase 2
• A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or LegRecruitingNCT04332874Phase 2
• Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral MelanomaRecruitingNCT04331093Phase 2
• Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical CarcinomaRecruitingNCT04318730Phase 2
• Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal MelanomaRecruitingNCT04318717Phase 2
• Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cmRecruitingNCT04317534Phase 2
• A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)RecruitingNCT04302025Phase 2
• to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC)Not yet recruitingNCT04301739Phase 3
• Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic CholangiocarcinomaRecruitingNCT04299581Phase 2
• Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)RecruitingNCT04278222Phase 2
• Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible SensitivityRecruitingNCT04273061Phase 2
• Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment With or Without Sonrotoclax for Patients With Richter TransformationRecruitingNCT04271956Phase 2
• Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])RecruitingNCT04267848Phase 3
• Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune InfiltrateRecruitingNCT04262687Phase 2
• Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/ImmunotherapyRecruitingNCT04253964Phase 2
• DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular CarcinomaRecruitingNCT04248569Phase 1
• Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin LymphomaRecruitingNCT04233294Phase 2
• Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/BevacizumabRecruitingNCT04224636Phase 2
• Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal CarcinomaRecruitingNCT04221516Phase 2
• Nivolumab for Treatment of Squamous Cell Carcinoma of the SkinRecruitingNCT04204837Phase 2
• Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.RecruitingNCT04202809Phase 2
• Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)RecruitingNCT04198766Phase 1/2
• Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal CarcinomaRecruitingNCT04143984Phase 2
• Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced MalignanciesRecruitingNCT04137900Phase 1
• HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized TrialRecruitingNCT04135690Phase 2
• Checkpoint Inhibition In Pediatric Hepatocellular CarcinomaRecruitingNCT04134559Phase 2
• Phase I Study of KN044 in Locally Advanced/Metastatic Solid TumorsRecruitingNCT04126590Phase 1
• Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal CancerRecruitingNCT04109755Phase 2
• DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancErRecruitingNCT04106115Phase 1/2
• Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal CancerRecruitingNCT04083365Phase 2
• MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue SarcomaRecruitingNCT04074564Early Phase 1
• Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)RecruitingNCT04070040Phase 2
• Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCLNot yet recruitingNCT04052659Phase 2
• Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)RecruitingNCT04040361Phase 2
• Targeted Pathway Inhibition in Patients With Pancreatic CancerRecruitingNCT04005690Early Phase 1
• The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon CancerRecruitingNCT03985891Phase 1/2
• Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast CancerRecruitingNCT03971045Phase 2
• IT or IA Infusion of PD1/PDL1/CTLA4 Inhibitors Versus IV for Immunotherapy of Head/Neck Cancers (HNC)RecruitingNCT03952065Phase 2/3
• Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular CarcinomaRecruitingNCT03949231Phase 3
• Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver CancerRecruitingNCT03942328Phase 1/2
• A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard TherapyRecruitingNCT03941574Phase 2
• Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal CancerRecruitingNCT03926338Phase 2
• PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma PatientsRecruitingNCT03907826Phase 3
• Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCCRecruitingNCT03899428Phase 2
• Pan Tumor Rollover StudyRecruitingNCT03899155Phase 2
• Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLCRecruitingNCT03872661Phase 2
• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingNCT03866382Phase 2
• A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI StudyRecruitingNCT03844256Phase 1/2
• Neoadjuvant Combination Immunotherapy for Stage III MelanomaRecruitingNCT03842943Phase 2
• INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory MalignanciesRecruitingNCT03838042Phase 1/2
• Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical ProstatectomyRecruitingNCT03821246Phase 2
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVORecruitingNCT03816345Phase 1
• Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IORecruitingNCT03815890Phase 2
• Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid TumorsRecruitingNCT03810339Phase 2
• Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor MalignanciesRecruitingNCT03772561Phase 1
• Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLCRecruitingNCT03769129Not applicable
• A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)RecruitingNCT03767075Phase 2
• Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)RecruitingNCT03760575Phase 1
• WIRE - Novel Treatments in Renal Cell CancerRecruitingNCT03741426Phase 2
• PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast CancerRecruitingNCT03740893Phase 2
• Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid TumorsRecruitingNCT03736889Phase 2
• Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLCRecruitingNCT03694236Phase 1/2
• ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsRecruitingNCT03686124Phase 1/2
• Evaluating the Effect of Nivolumab for Patients With In-transit Metastases Treated With Isolated Limb PerfusionRecruitingNCT03685890Phase 1/2
• Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin LymphomaRecruitingNCT03681561Phase 1/2
• Recurrent Ovarian CarcinoSarcoma Anti-pd-1 NiraparibRecruitingNCT03651206Phase 2/3
• Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin LymphomaRecruitingNCT03618550Phase 2
• Pembrolizumab in Treating Participants With LeukoplakiaRecruitingNCT03603223Phase 2
• Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) CancersRecruitingNCT03564340Phase 1/2
• Melanoma Metastasized to the Brain and SteroidsRecruitingNCT03563729Phase 2
• VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaRecruitingNCT03556228Phase 1/2
• Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc)RecruitingNCT03548428Phase 2
• Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal MalignanciesRecruitingNCT03539822Phase 1/2
• Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck CancerRecruitingNCT03532737Phase 2
• A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsRecruitingNCT03526835Phase 1/2
• Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell CarcinomaRecruitingNCT03521830Phase 2
• Trial of Pembrolizumab in Metastatic Castration Resistant Prostate CancerRecruitingNCT03506997Phase 2
• Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)RecruitingNCT03486873Phase 3

← Immune Checkpoint Inhibitors overview